A Phase 1 interventional study of Talineuren in Parkinson Disease, sponsored by InnoMedica Schweiz AG. Terminated at 1 site in Switzerland. Open to participants aged 30 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by InnoMedica Schweiz AG · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Parkinson Disease with a site in Switzerland — 31 open to participants now, 34 under way, none of them phase 3. Parkinson Disease · Switzerland.
Among the 85 studies in Parkinson Disease with a site in Switzerland, this one is the 40th largest by enrollment of the 67 interventional ones that give a count, is one of 11 that started in 2021, is one of 4 in phase 1, and was the 47th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →31 of the 85 studies in Parkinson Disease with a site in Switzerland are open now. Recruiting first, the newest first:
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18–75
Siegward -M. Elsas · Sites in Switzerland
Ages 50–79
University of Zurich · Sites in Switzerland
Ages 18+
University of Zurich · Sites in Switzerland
Alain Kaelin · Sites in Switzerland
Ages 50–80
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 4 · Phase 4 3
First in 2002; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 22 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 30 across the 67 interventional studies, 64 across the 18 observational. Of the 45 that completed or were terminated, 6 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 85 have an industry lead sponsor. The 10 most frequent:
InnoMedica Schweiz AG is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
InnoMedica Schweiz AG has 2 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
12 of the studies in Parkinson Disease with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06831500Julien BallyFeasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. | 2026-11 |
| NCT07485218University of Applied Sciences and Arts of Southern SwitzerlandMultidimensional Assessment of Fatigability in Older Adults Living in Southern Switzerland and Elderly With Parkinson's Disease | 2026-12 |
| NCT06608875University of ZurichPrecision Sensorimotor Neurorehabilitation Through Personalized Stimulation Loops | 2026-12 |
| NCT05765110Insel Gruppe AG, University Hospital BernSPEECH as Biomarker for Emotion, Movement and cOgnition in Parkinson's Disease | 2026-12-31 |
| NCT07802509Klinik ValensDoes Hippotherapy Have an Effect on Mobility, Gait, Balance and Perceived Health-related Quality of Life in Persons With Parkinson's Disease? | 2027-01-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 85 studies in Parkinson Disease with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is an open-label, single ascending dose escalation followed by a multiple administration dose at the maximal suitable dose (MSD). The investigational Medicinal Product (IMP) is given as an add-on therapy.
Talineuren consists of GM1 (monosialotetrahexosylganglioside), the pharmacologically active ingredient, associated with a proprietary lipid formulation assembled as liposomes.
The primary objective is to demonstrate the safety of TLN administration intravenously in Parkinson patients.
Secondary objectives are the determination of the maximal suitable dose based on the safety profile and preliminary efficacy, as well as the determination of the pharmacokinetics (PK) profile.
The ganglioside lipid GM1 has been described in the literature as a neuroprotective agent.
Several clinical studies have shown that GM1 improves the condition of Parkinson's disease patients.
Talineuren consists of the pharmacologically active ingredient GM1, associated with a proprietary lipid formulation assembled as liposomes. Talineuren has been developed to improve the delivery and bioavailability of GM1.
The primary objective of this trial is to demonstrate the feasibility and safety of intravenous Talineuren administration in Parkinson's disease patients.
The secondary objectives are:
This trial aims to investigate the safety of the novel formulation of GM1, Talineuren.
To that extent a three-part trial was designed: Part 1- Dose escalation Part 2- Dose consolidation Part 3- Dose consolidation with intrapatient dosing
Part 1- rapid dose escalation scheme from 6 mg to 720 mg of Talineuren formulated GM1 in 3 patients. Optional treatment prolongations for 8 weeks (Amendment 1), 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4), and 12 months (Amendment 5).
Part 2- multiple dosing of Talineuren over 8 weeks in 9 patients to validate the safety profile of the maximum suitable dose. Optional treatment prolongations for 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4), and 12 months (Amendment 5).
Part 3- rapid dose escalation scheme from 6 mg to 720 mg of Talineuren followed by multiple doses of 720mg Talineuren for up to 8 months in 10 patients (Amendment 3). Additional Follow-up visit (washout timepoint) 4 months after final assessment (Amendment 6).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
14 doses of GM1 Ganglioside 6, 12, 60, 120, 180, 240, 300, 360, 420, 480, 540, 600, 660, 720 mg. Optional treatment prolongations for 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4) and 12 months (Amendment 5).
Drug: Talineuren
8 repeated doses of GM1 Ganglioside tbd from the escalation dose (maximum suitable dose). Optional treatment prolongations for 16 weeks (Amendment 2), 8 months (Amendment 3), 4 months (Amendment 4) and 12 months (Amendment 5).
Drug: Talineuren
8 months repeated doses of 720mg GM1 Ganglioside (Amendment 3).
Drug: Talineuren
Talineuren is a liposomal formulation of the GM1 Ganglioside for intravenous administration
Also known as: liposomal GM1
Occurence of adverse events (safety)
Number and kinds of adverse events (AEs)
Time frame: 8 to 134 weeks
Occurence of serious adverse events (safety)
Number and kinds of serious adverse events (SAEs)
Time frame: 8 to 134 weeks
Occurence of other safety-related signs (safety)
Number and kinds of other safety-related signs
Time frame: 8 to 134 weeks
Levodopa challenge (LDC) test
Assessing the patients' condition via the LDC test (MDS-UPDRS-3 score)
Time frame: 8 to 134 weeks
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Assessing the patients' condition via the test
Time frame: 8 to 134 weeks
Epworth Sleepiness Scale (ESS)
Assessing the patients' condition via the test
Time frame: 8 to 134 weeks
Parkinson's Disease Questionnaire (PDQ-39)
Assessing the patients' condition via the test
Time frame: 8 to 134 weeks
Change in Parkinson's medication
Assessing the patients' condition via the change in their pre-existing Parkinson's medication
Time frame: 8 to 134 weeks
Starkstein Apathy Scale (SAS)
Assessing the patients' condition via the test
Time frame: 8 to 134 weeks
Montreal Cognitive Assessment (MoCA)
Assessing the patients' condition via the test
Time frame: 8 to 134 weeks
Beck's Depression Inventory (BDI)
Assessing the patients' condition via the test
Time frame: 8 to 134 weeks
Non-Motor Symptoms Questionnaire (NMSQuest)
Assessing the patients' condition via the test
Time frame: 8 to 134 weeks
Maximum Observed Drug Concentration (Cmax) in serum
Pharmacokinetics (PK) of total GM1 in serum over the first 96 h
Time frame: 8 to 15 weeks
Time of Maximum Drug Concentration (Tmax) in serum
Pharmacokinetics (PK) of total GM1 in serum over the first 96 h
Time frame: 8 to 15 weeks
Area Under the Curve to infinity (AUCinf.) in serum
Pharmacokinetics (PK) of total GM1 in serum over the first 96 h
Time frame: 8 to 15 weeks
half-life (t1/2)
Pharmacokinetics (PK) of total GM1 in serum over the first 96 h
Time frame: 8 to 15 weeks
Clearance (CL)
Pharmacokinetics (PK) of total GM1 in serum over the first 96 h
Time frame: 8 to 15 weeks
Volume of distribution (Vd)
Pharmacokinetics (PK) of total GM1 in serum over the first 96 h
Time frame: 8 to 15 weeks
Plan to share: No
Ran from Dec 2021 to primary completion in Aug 2025, 43 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
InnoMedica Schweiz AG